- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06483789
Eficacia y seguridad del HB-1 para el trastorno de pánico: un ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo
The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo and two monotherapies, in male and female adult patients aged 18 to 65 years, inclusive, with Panic Disorder.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
This is a multicenter, randomized, double-blind, placebo-controlled trial. All patients with Panic Disorder, with or without specified co-morbidities, who meet all of the inclusion and none of the exclusion criteria will be eligible. Patients and researchers will be blinded to their treatment group.
The study will enroll approximately 240 (up to 600) adult patients who meet the diagnosis of panic disorder.
Patients will be treated for 12 weeks followed by a safety follow up visit one week after their last dose of study treatment.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Australian Capital Territory
-
Canberra, Australian Capital Territory, Australia, 2617
- Paratus Clinical Research Canberra
-
-
New South Wales
-
Blacktown, New South Wales, Australia, 2148
- Paratus Clinical Research Western Sydney
-
Charlestown, New South Wales, Australia, 2290
- Novatrials
-
Darlinghurst, New South Wales, Australia, 2010
- East Sydney Doctors
-
Darlinghurst, New South Wales, Australia, 2010
- Momentum Clinical Research Darlinghurst
-
Miranda, New South Wales, Australia, 2228
- Canopy Clinical Sutherland
-
Waitara, New South Wales, Australia, 2077
- Innovate Clinical Research
-
Westmead, New South Wales, Australia, 2145
- Westmead Hospital
-
Wollongong, New South Wales, Australia, 2500
- Canopy Clinical Wollongong
-
-
Queensland
-
Herston, Queensland, Australia, 4006
- Paratus Clinical Research Brisbane
-
Mackay, Queensland, Australia, 4740
- Mackay Hospital and Health Service
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- South Australian Health and Medical Research Institute
-
-
Victoria
-
Carlton, Victoria, Australia, 3053
- NeuroCentrix
-
Frankston, Victoria, Australia, 3199
- Peninsula Therapeutic and Research Group
-
Melbourne, Victoria, Australia, 3004
- Ramsay Clinic Albert Road
-
Melbourne, Victoria, Australia, 3004
- Multidisciplinary Alfred Psychiatry Research Clinic
-
Northcote, Victoria, Australia, 3070
- Paratus Clinical Research Melbourne
-
Torquay, Victoria, Australia, 3228
- Clinical Trials Institute
-
-
Western Australia
-
West Perth, Western Australia, Australia, 6005
- Clinitrials
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female aged 18 to 65 years old, inclusive, at the time of informed consent.
- Meets Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) Criteria for Panic Disorder.
- Minimum of one full, unexpected panic attack in week prior to screening (via Diagnostic and Statistical Manual of Mental Disorders 5th edition [DSM-V] based structured interview).
- Medically stable on current medication regimen for at least 3 months (including as needed [PRN] medications), as determined by Investigator.
- Willing to remain on current doses of other psychiatric medications throughout the length of the trial.
- Willing and able to safely stop / avoid any of the following prior to study trial: Inhibitors or inducers of CYP3A4 (grapefruit juice, erythromycin, ritonavir, telithromycin, rifampin), HMG-CoA Reductase Inhibitors (Simvastatin, Lovastatin, Atorvastatin), Beta Blockers (Timolol eyedrops, Metoprolol), Neuromuscular Blocking Agents (curare-like and depolarizing), Antihypertensive Agents (Prazosin and vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers), Inhalation Anesthetics, Disopyramide, Flecainide, Quinidine, Cimetidine, Lithium, Carbamazepine, Phenobarbital, Cyclosporine, Digitalis, Aliskiren, Ramipril and Ramiprilat, aspirin, propranolol.
- Willing and able to safely stop / avoid sensitive P-glycoprotein inhibitors.
- Willing to take HB-1, telmisartan, verapamil, or placebo.
- Willing and able to provide informed consent indicating an understanding of the requirements of the study and a willingness to comply with scheduled visits and all study procedures.
- Female subjects must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or commit to use 2 acceptable forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 4 months following the last dose of study treatment. Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms ± spermicide) for the duration of the study and for 4 months following the last dose of study treatment. Individuals who are involved exclusively in same-sex relationships are exempt from the birth control requirements but must agree to abide by the recommendations if they do engage in a heterosexual relationship.
- Female subjects who are women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening, within 7 days of dosing with study treatment.
Exclusion Criteria:
- Any concomitant disease, condition, or treatment that could interfere with the conduct of the study, or that would, in the opinion of the Investigator or Sponsor, pose an unacceptable risk to the participant in the study or interfere with the interpretation of study data.
- Concurrent treatment with benzodiazepines (e.g. alprazolam, diazepam, clonazepam, lorazepam) as assessed by clinical interview and urine toxicology testing.
- Severe Agoraphobia (Panic Disorder Symptom Severity Scale (PDSS) Item 4 "agoraphobic fear/avoidance" > 2).
- Severe Generalized Anxiety (Hamilton Anxiety Rating Scale [HAM-A] Total Score > 23).
- Prior lifetime history of suicide attempt, Columbia Suicide Severity Rating Scale (C-SSRS) ≥ 4 in the past 6 months or prior lifetime history of hospitalization for depression.
- Diagnosis of Substance Use Disorder, Obsessive-Compulsive Disorder (OCD), Bipolar I, Bipolar II disorder or schizoaffective or other psychotic disorders (per Structure Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) [SCID-V].
- Severe uncontrolled cardiac disease within 6 months of Screening, including but not limited to uncontrolled hypertension, hypotension (defined as below 90/60); unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA).
- Any clinically significant electrocardiogram (ECG) abnormalities at screening.
- Inadequate hepatic function defined as total bilirubin > 1.5 × the upper limit of normal (ULN) ranges of each institution, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 3 × the ULN range of each institution.
- Inadequate renal function defined as serum creatinine > 1.5 × the upper limit of normal (ULN) range of each institution and/or estimated glomerular filtration rate (eGFR) < 60.
- Any clinically significant abnormalities in clinical laboratory assessments as assessed by the Investigator.
- Any other systemic conditions or organ abnormalities that in the opinion of the Investigator may interfere with the conduct and/or interpretation of the current study.
- Unable to complete neuropsychological testing.
- Already on treatment with either telmisartan or verapamil or both.
- Has a history of hypersensitivity or severe allergic reaction to either telmisartan or verapamil, or any component of either licensed drug.
- Documented contraindication to taking telmisartan or verapamil: (e.g., Duchenne's muscular dystrophy, myasthenia gravis).
- Pregnant or breastfeeding.
- Participation in another current clinical trial or prior trial within the last three months.
- Urinalysis evidence of exposure to substances that may interfere with HB-1 testing (per investigator discretion).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: HB-1
HB-1 fixed dose, once daily. |
HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
Otros nombres:
|
|
Experimental: Telmisartan
Telmisartan fixed dose, once daily. |
Telmisartan will be supplied as a single active pharmaceutical ingredient tablet.
Otros nombres:
|
|
Experimental: Verapamil
Verapamil fixed dose, once daily. |
Verapamil will be supplied as a single active pharmaceutical ingredient tablet.
Otros nombres:
|
|
Comparador de placebos: Placebo
Placebo treatment, once daily |
Matched Placebo will be supplied as a tablet.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Unexpected Panic Attacks
Periodo de tiempo: Screening, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11, and Week 12
|
Efficacy will be evaluated through a comparison of the number of unexpected panic attack days (over the last 10 weeks in a 12-week treatment period) from Screening as compared to protocol-specified timepoints per protocol. |
Screening, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11, and Week 12
|
|
Incidence of Treatment-Emergent Adverse Events
Periodo de tiempo: Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12 and Week 13.
|
Safety will be evaluated through the monitoring of Adverse Events and the review of clinically significant changes in routine laboratory tests, ECGs, and orthostatic vital signs. |
Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12 and Week 13.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Clinical Global Impression-Severity Scale (CGI-S)
Periodo de tiempo: Baseline, Week 4, Week 8 and Week 12
|
Efficacy will be evaluated through an evaluation in Clinical Global Impression Severity scale (CGI-S) scores from Baseline as compared to protocol-specified timepoints per protocol. The Clinical Global Impression Severity Scale is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). |
Baseline, Week 4, Week 8 and Week 12
|
|
Change in Panic Disorder Symptom Severity Scale (PDSS)
Periodo de tiempo: Screening, Week 4, Week 8 and Week 12
|
Efficacy will be evaluated through an evaluation in Panic Disorder Symptom Severity Scale (PDSS) scores from Screening as compared to protocol-specified timepoints per protocol. |
Screening, Week 4, Week 8 and Week 12
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Prof. Malcolm Hopwood, Ramsay Clinic Albert Road
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Desórdenes de ansiedad
- Desordenes mentales
- Trastorno de pánico
- Químicos orgánicos
- Compuestos heterocíclicos
- Benzimidazoles
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Preparaciones farmacéuticas
- Técnicas de investigación
- Hidrocarburos
- Hidrocarburos, cíclico
- Hidrocarburos, aromáticos
- Amina
- Tecnología, farmacéutica
- Derivados de benceno
- Fenetilaminas
- Etilaminas
- Compuestos de bifenilo
- Telmisartán
- Verapamilo
- Formas de dosificación
Otros números de identificación del estudio
- HB-PD-002
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .